Cyclopentylpyrazole CDK2 Inhibitors Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK inhibitors, such as CDK4/6 and CDK1, have side effects like neutropenia and gastrointestinal toxicity, and there is a need for selective inhibitors of CDK2 to treat CDK2-mediated disorders without affecting normal tissues.
Innovation Solution
Development of cyclopentylpyrazole inhibitors of CDK2, as represented by Formula (I), which are used in pharmaceutical compositions to treat CDK2-mediated diseases like cancer, with specific structural definitions for the compounds and their use in medicaments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK4/6 inhibitors are used to treat cancer, then cell proliferation is controlled, but neutropenia and other side effects occur
Solution Approach 1:
The patent applies local quality by designing a inhibitor with specific molecular characteristics (cyclopentylpyrazole core structure with particular substituents) that confers selectivity for CDK2 over CDK4/6 and CDK1. This localized molecular design enables the drug to target only the intended kinase isoform, treating cancer while avoiding off-target effects that cause neutropenia and other side effects.
2Reliability
If CDK1 inhibitors are used to control cell cycle, then cell proliferation is regulated, but gastrointestinal toxicity occurs
Solution Approach 1:
The inhibitor employs local quality through its specific molecular structure (Formula I compounds with cyclopentylpyrazole core) that provides high selectivity for CDK2. This selective binding profile ensures that CDK1 remains unaffected, thereby preventing gastrointestinal toxicity while maintaining effective cell cycle regulation through CDK2 inhibition.
3Reliability
If non-selective CDK inhibitors are used, then broad cell proliferation control is achieved, but impact on normal tissues increases
Solution Approach 1:
The patent implements local quality by designing inhibitors with specific molecular features (substituted cyclopentylpyrazole structures) that enable selective binding to CDK2's unique active site architecture. This selectivity allows broad cell proliferation control through CDK2 inhibition while sparing normal tissues that rely on CDK4/6 and CDK1 for their cell cycle regulation.
Solution Approach 2:
The inhibitor applies segmentation by targeting a specific segment (CDK2 isoform) of the broader CDK family rather than inhibiting all CDKs uniformly. The molecular structure is designed to exploit subtle differences in the ATP-binding pockets of various CDK isoforms, achieving selective inhibition of CDK2 while leaving other CDKs unaffected, thus controlling proliferation without harming normal tissues.
Data Source
AI summary
Described here are compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and their use and preparation.